Many trials are now underway to find an effective treatment for COVID-19. To show effectiveness a number of endpoints can be considered – hospitalization duration, ventilator use, and obviously mortality. Is there a preference?

In this webinar we will discuss the issue of selection of a suitable endpoints in the context of FDA’s recent guidance, and the related study design and analytical issues.

The date of Webinar: September 16th at 1pm (EST)

Overview: Many trials are now underway to find an effective treatment for COVID-19. To show effectiveness of a treatment a number of endpoints can be considered including duration of hospitalization, ventilator use, mortality etc. Is there a preference? Does it depend n the phase of the study?

In this webinar we will discuss the issue of selection of suitable endpoints in the context of recent regulatory guidance documents. We will also touch upon the related study design and analytical issues. 

If you join us at this webinar you’ll learn:

• A framework of endpoint selection
• Hierarchy of endpoints
• FDA and other Regulatory guidance on the endpoints for COVID studies
• Associated points to consider when choosing endpoints